Navigation Links
Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
Date:9/25/2013

CORK, Ireland, September 25, 2013 /PRNewswire/ --

Janssen R&D Ireland (Janssen) announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) against HIV infection.

Under the terms of the agreement, a Drug Development program of PATH, an international nonprofit organization that transforms global health through innovation, has the right to develop rilpivirine long-acting formulation as a possible new way to prevent HIV infection. PATH has the intent to conduct prophylaxis clinical trials in collaboration with partners including the HIV Prevention Trials Network. Following the completion of the clinical Phase 2 program, PATH and Janssen will evaluate entering into a late stage development agreement covering the use of rilpivirine as PrEP for uninfected individuals at high risk of acquiring HIV.

"Rilpivirine is an important treatment option for patients today and we are pleased to work with PATH to evaluate it as an injectable depot formulation that may help to reduce the spread of infection," said Wim Parys, Global Head of Research & Development, Janssen Global Health. "We believe that evaluating a long-acting formulation, which could help improve adherence in a PrEP regimen, is an important part of the Janssen commitment to the global fight against HIV and AIDS."

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is currently commercialized by Janssen for the oral, once daily treatment of HIV-1, in combination with other antiretroviral agents (ARVs), in ARV treatment-naïve adults, and in most countries, in patients with a viral load less than or equal to 100,000 HIV-1RNA copies/mL.

This license agreement with P
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
2. Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
3. Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
4. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
7. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
8. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
9. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
10. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management ... and Regeneron will host an IR Thematic Conference Call on Alirocumab ... 2014 , Baird 2014 Healthcare Conference at 4:05 ... , Citi,s 9 th Annual Biotech Conference at ... , Morgan Stanley Global Healthcare Conference at 8:45 ...
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... ALBANY, New York , August 19, 2014 /PRNewswire/ ... " Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... valued at USD 218.5 million in 2013 and is ... 2014 to 2020, to reach an estimated value of ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... Tappahannock, Va. (PRWEB) August 20, 2014 ... Dr. William Dameron , who joined its Warsaw Medical ... additional physician specialized in Family Medicine, is accepting new ... University School of Medicine, completed his residency at the ... relocating back to Virginia. , “I really like the ...
(Date:8/19/2014)... As moms and dads prepare their children to go ... normal routine of dropping their little ones off at daycare ... encourages them to use the opportunity to implement a ... Yarker explains, “Kids have small tummies, short attention spans, and ... food handouts, use snack time as another daily opportunity to ...
(Date:8/19/2014)... 2014 Crosley Law Firm, PC has reached ... against Lone Star Bakery for an undisclosed amount. The two ... and May of 2011, respectively. The injuries were caused by ... severe injury to the left hand of each man. , ... Bakery was short-staffed, having lost 200 of its, 500 workers ...
(Date:8/19/2014)... An editorial published in this week,s JAMA ... assessment tools when considering how to treat patients. Written ... Medical Center and chair of pediatrics at Boston University ... JAMA , the editorial examines results of a ... as an example of how doctors can often over-emphasize ...
Breaking Medicine News(10 mins):Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2
... Rating ... , ... (PRWEB) March 23, 2010 -- The Hartville Group Inc., which provides pet health insurance ... Insurance, Hartville Pet Insurance, and the Petshealth Care Plan, has received an A+ rating ...
... ... ... Sir Richard Bowlby keynotes ,Linking Forces, educational event with 16-year history in community , ... , ...
... , March 23 InterMune, Inc. (Nasdaq: ... (MAA), submitted on March 2 seeking approval of ... adults, was validated by the European Medicines Agency (EMA). Validation ... is complete and that the review process will begin on ...
... ... for Haiti survivors. , ... (PRWEB) March 23, 2010 -- Just like any other business, non-profit organizations must ... VoiceNation,s call center agents and auto attendants assist to fill the ...
... ... sustainable solution to the crisis in Haiti. The flexibility of these products can easily make ... ... -- Bosoley Solar Energy’s line of solar lights brings vital illumination to residents and aid ...
... ... than first thought. , ... -- Long known for being an excellent source of fiber, two recent studies suggest that apples ... antioxidants, previous research has suggested that apples may prevent or reduce the risks of certain types ...
Cached Medicine News:Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 2Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 2Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 4Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 2Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 4Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 6Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 7Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 2Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 3Health News:Bosoley Solar Light Set to Bring Haiti Out of the Post-Earthquake Darkness 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: